IMI launches 14th call

The JTI Innovative Medicines Initiative 2 (IMI JU) has launched its fourteenth call for proposals under the IMI 2 programme with topics on immune diseases, imaging, machine learning, and digital clinical trials. The Stage 1 submission deadline is June 14, 2018. The indicative budget available for the call with identifier H2020-JTI-IMI2-2018-14-two-stage is € 167,277,360, of which € 84,920,360 is from EFPIA companies and IMI2 Associated Partners and € 82,357,000 from the IMI2 JU.

The call includes four topics:

• Topic 1: Targeted immune intervention for the management of non-response and relapse;
• Topic 2: Non-invasive clinical molecular imaging of immune cells;
• Topic 3: Development of a platform for federated and privacy-preserving machine learning in support of drug discovery;
• Topic 4: Centre of excellence – remote decentralised clinical trials.

The first webinar for the call is scheduled for Friday March 16. 

The Innovative Medicines Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).